Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
Deborah Bradley(University of Michigan), Maha Hussain(Northwestern University), Glenn Liu(University of Wisconsin Carbone Cancer Center), James A. Zwiebel(National Institutes of Health), Rodney L. Dunn(University of Michigan), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Walter M. Stadler(Project HOPE), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), David C. Smith(University of Michigan), Роберто Пили(Jacobs Institute)
Cited by 148
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k